Related Experiment Video
Updated: Apr 14, 2026
Clinical Application of Single-Surgeon, Three-Port, Laparoscopic Resection for Colorectal Cancer with Natural Orifice Specimen Extraction
Published on: March 24, 2023
Patient preferences of a resect and discard paradigm
Hongha T Vu1, Gregory S Sayuk1, Neil Gupta1
1Washington University School of Medicine, Washington University in St. Louis, St. Louis, Missouri.
Background:
Resect and discard is a new paradigm for management of diminutive polyps. It is unknown whether patients will embrace this new paradigm in which small polyps would not be sent for histopathologic review.
Objective:
To determine whether patients would be willing to pay for pathology costs with their own money and which factors influence patients' decisions to pay or not pay for pathology costs with their own money.
Design:
Single-center, prospective, survey study.
Setting:
Hospital outpatient endoscopy center.
Patients:
Adults undergoing colonoscopy for screening or routine polyp surveillance.
Interventions:
Patient survey.
Main Outcome Measurements:
Willingness to pay out-of-pocket for pathology costs when a diminutive polyp is found and factors that influence patients' decisions to pay or not pay for pathology costs with their own money.
Results:
A total of 500 participants completed the survey. A total of 360 respondents (71.9%) indicated a hypothetical willingness to pay out-of-pocket for histopathologic polyp analysis if this interpretation was not covered by insurance. Patient factors significantly associated with willingness to pay for polyp analysis included higher income and education and female sex.
Limitations:
Single center, hypothetical situation.
Conclusion:
Over two-thirds of patients were willing to pay to have their diminutive polyp sent for pathologic evaluation if their insurance carrier would not pay the cost. Factors associated with willingness to pay included higher income, higher education, and female sex. Patients who were unwilling to pay raised concerns about cost and are less concerned about cancer risk compared with those willing to pay. (
Clinical Trial Registration Number:
NCT02305251.).
